Marijuana Legalization Activist Could Lead Trump’s FDA

By Tom Angell for

Mike Liszewski of Americans for Safe Access told that FDA’s current approval process for botanicals is “unworkable” and that as a result, very few have been approved. “O’Neill’s appointment could lead to an overhaul of rules pertaining to botanical medicine, which could create a much friendlier environment for research and approval of cannabis and other botanicals,” he said.